Post-marketing Study Assessing the Long-Term Safety of Abatacept

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: Abatacept

Study type: Observational

Funder types: Industry

Identifiers

NCT02169544

IM101-488

Details and patient eligibility

About

The purpose of this study is to evaluate the risk of infections and malignancies among Rheumatoid Arthritis (RA) patients treated with Abatacept compared to other RA treatments.

Enrollment: 100,000 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Patient has at least two claims for RA (714.xx) in the 180 days prior to and including the index date (baseline period)
• Patient is aged 18 years or older on the index date
• Patient was enrolled in the database for at least 180 days before the index date
• Patient is newly prescribed Abatacept or another RA treatment and has at least two claims for the treatment

Trial design

100,000 participants in 2 patient groups

RA patients who are prescribed Abatacept

Description:

Abatacept

Treatment:

Drug: Abatacept

Patients who are prescribed other RA treatments